New hope for myelofibrosis patients: experimental pill targets resistant disease

NCT ID NCT06343805

Recruiting now Disease control Sponsor: Ajax Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an experimental oral drug, AJ1-11095, in about 76 adults with myelofibrosis (a type of bone marrow cancer) whose disease has stopped responding to standard JAK2 inhibitor therapy. The main goals are to check the drug's safety, find the best dose, and see if it can reduce symptoms and spleen size. Participants must have moderate-to-high risk disease and significant symptoms or spleen enlargement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

platelet membrane fluidity primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PET-MF PMF POST POLYCYTHEMIA VERA MYELOFIBROSIS POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS PPV-MF PRIMARY MYELOFIBROSIS

Contacts and locations

Locations

AP-HP Hopital Saint-Louis
RECRUITING

Paris, France
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering
RECRUITING

New York, New York, 10021, United States
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
NOT_YET_RECRUITING

Milan, Italy, Italy
Genesis Cancer Care UK Limited - Oxford
NOT_YET_RECRUITING

Oxford, UK, United Kingdom
Guy's Hospital
NOT_YET_RECRUITING

London, UK, United Kingdom
Hospital Clinic Barcelona
RECRUITING

Barcelona, Spain
Hospital General Universitario Gregorio Maranon
RECRUITING

Madrid, Spain, Spain
Hospital Universitario Ramon y Cajal
RECRUITING

Madrid, Spain
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
NOT_YET_RECRUITING

Bologna, Italy, Italy
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Moffitt Cancer Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Stanford Cancer Institute
RECRUITING

Palo Alto, California, 94304, United States
The Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
University of Cincinnati
RECRUITING

Cincinnati, Ohio, 45221, United States
University of Kansas Medical Center
RECRUITING

Kansas City, Kansas, 66160, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.